QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
OTCMKTS:AZNCF

AstraZeneca (AZNCF) Stock Forecast, Price & News

$146.90
+1.45 (+1.00%)
(As of 06/7/2023 ET)
Compare
Today's Range
$146.90
▼
$147.29
50-Day Range
$137.50
▼
$153.10
52-Week Range
$104.50
▼
$153.10
Volume
1,739 shs
Average Volume
3,548 shs
Market Capitalization
N/A
P/E Ratio
180.02
Dividend Yield
1.91%
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest

AstraZeneca MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.18mentions of AstraZeneca in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.92 out of 5 stars

See Top Rated MarketRank™ Stocks Here

AZNCF stock logo

About AstraZeneca (OTCMKTS:AZNCF) Stock

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Receive AZNCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AZNCF Stock News Headlines

June 1, 2023 | marketbeat.com
20 Best Healthcare Dividend Stocks to Invest in (AZNCF)
Healthcare, like many other sectors, produces dividends. Learn more about how to invest in healthcare trends and earn dividends along the way with MarketBeat.
June 6, 2023 | bloomberg.com
AstraZeneca’s Japan Partner to Go Solo on Future Cancer Drugs
June 7, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
June 6, 2023 | reuters.com
Sanofi-AstraZeneca's preventive RSV therapy appears safe, says FDA staff
June 5, 2023 | msn.com
Lung cancer deaths cut in half with AstraZeneca pill, large trial finds
June 5, 2023 | marketwatch.com
AstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in Trial
June 5, 2023 | lse.co.uk
AstraZeneca and Daiichi Sankyo report progress in cancer drug trials
June 5, 2023 | lse.co.uk
AstraZeneca stops Andexxa trial early, Tagrisso reduces death risk
June 7, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
June 5, 2023 | marketwatch.com
AstraZeneca to Stop Intracranial Hemorrhage Drug Trial After Criteria Met
June 5, 2023 | msn.com
Stocks Mixed, Week Ahead, OPEC Cuts, Palo Alto Networks Joins S&P 500, AstraZeneca Lung Cancer Trial - 5 Things To Know
June 4, 2023 | msn.com
AstraZeneca's Imfinzi shows positive response in gastric cancers
June 4, 2023 | msn.com
AstraZeneca lung cancer drug halves death risk from disease, landmark study finds
June 4, 2023 | msn.com
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients
June 4, 2023 | ft.com
AstraZeneca defies geopolitics to bet on China
June 2, 2023 | tmcnet.com
AESOP Technology Announces Collaboration with AstraZeneca Taiwan on Medigator: Advancing Shared Decision-Making in Precision Medicine
June 2, 2023 | marketwatch.com
AstraZeneca Says Imfinzi Data Shows Improved Response in Gastric Cancers
June 2, 2023 | msn.com
AstraZeneca announces new drug to treat lung and liver cancers now available in the UAE
June 1, 2023 | thetimes.co.uk
AstraZeneca prostate cancer treatment wins US approval
June 1, 2023 | msn.com
Pharma giant AstraZeneca to halt development of a treatment for Crohn's disease
June 1, 2023 | marketwatch.com
AstraZeneca Says US Approved Lynparza as a Prostate Cancer Treatment
June 1, 2023 | marketwatch.com
AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program
June 1, 2023 | msn.com
AstraZeneca gains US approval for prostate cancer combo treatment
May 27, 2023 | msn.com
AstraZeneca aids government in fight vs kidney disease
May 26, 2023 | finance.yahoo.com
AstraZeneca PLC: Reaffirming BUY; strong product pipeline
May 26, 2023 | lse.co.uk
TOP NEWS: AstraZeneca's Ultomiris wins another approval in Japan
May 26, 2023 | msn.com
AstraZeneca announces good results from endometrial cancer trial
See More Headlines

AZNCF Price History

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals: Major
Sub-Industry
N/A
Sector
Health Technology
Current Symbol
OTCMKTS:AZNCF
CUSIP
N/A
CIK
901832
Web
N/A
Phone
442037495000
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
180.02
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Pascal Soriot
    Chief Executive Officer & Executive Director
  • Pam P. Cheng
    Executive VP-Operations & Information Technology
  • Aradhana Sarin
    Chief Financial Officer & Executive Director
  • Menelas NICOLAS Pangalos
    EVP-Biopharmaceuticals Research & Development
  • Cindy L. Hoots
    Chief Digital & Information Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













AZNCF Stock - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZNCF shares.
View AZNCF analyst ratings or view top-rated stocks.

How have AZNCF shares performed in 2023?

AstraZeneca's stock was trading at $139.28 at the beginning of 2023. Since then, AZNCF shares have increased by 5.5% and is now trading at $146.90.
View the best growth stocks for 2023 here.

Are investors shorting AstraZeneca?

AstraZeneca saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 502,800 shares, a decline of 9.5% from the April 15th total of 555,700 shares. Based on an average daily volume of 21,500 shares, the days-to-cover ratio is currently 23.4 days.
View AstraZeneca's Short Interest.

Is AstraZeneca a good dividend stock?

AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

What is AstraZeneca's stock symbol?

AstraZeneca trades on the OTCMKTS under the ticker symbol "AZNCF."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Common Asset Management LLC (0.00%) and Vigilant Capital Management LLC (0.00%).

How do I buy shares of AstraZeneca?

Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZNCF stock can currently be purchased for approximately $146.90.

How can I contact AstraZeneca?

The company can be reached via phone at 442037495000.

This page (OTCMKTS:AZNCF) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -